Shares of Viking Therapeutics, a clinical-stage biotechnology firm, rallied significantly, closing at $34.34 with an 11.44% gain. Investors showed renewed enthusiasm from strong clinical trial data and acquisition rumors by big pharma.
VK2735 Phase 2 VENTURE Trial Results
The key driver was positive data from VK2735, Viking's obesity drug candidate. In the Phase 2 VENTURE study, participants achieved an average 14.7% weight reduction.
Precision tracking for your journey
Join thousands using Shotlee to accurately track GLP-1 medications and side effects.
📱 Get the Shotlee App
Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!